no, 1% chance of being a blockbuster drug. Everything hinges on it being DMOAD, of which its Phase 3 trial isnt even going for. Based on the IND submission, its just another pain relief drug. They're trying to hint at DMOAD on low numbers but that means absolutely nothing to the medical community. If they were actually confident of DMOAD, why not add MRI into the equation? Evidence on biomarkers is suspect at best. might make for a nice headline if it sees a difference in any number of what, 15 that its testing for? will claim it as a win but reality is - barely means anything without radiographic evidence. my views
no, 1% chance of being a blockbuster drug. Everything hinges on...
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.020(8.00%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 23.0¢ | $235.8K | 980.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 100000 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 6521 | 2 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |